AstraZeneca PLC (AZN) stock price

AstraZeneca PLC (AZN) is a Healthcare · Drug Manufacturers - General company listed on NASDAQ. Price $166.57 (+0.26%), Market cap $287.17B, P/E ratio 27.89, 52-week low–high $68.72 ~ $209.48.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhal

Key metrics

• Price: $166.57 (+0.26%)
• Market cap: $287.17B
• P/E ratio: 27.89
• 52-week low–high: $68.72 ~ $209.48
• Sector: Healthcare
• Industry: Drug Manufacturers - General
• Exchange: NASDAQ

Financial statements, price targets, institutional (13F) holdings and related news for AstraZeneca PLC are updated in real time on BlackAll Trade.

AstraZeneca PLC financial summary

Analyst outlook

• Analyst consensus: 4.5556

Key ratios · profitability · growth

• P/B ratio: 5.99
• Profit margin: 0.17%
• Operating margin: 0.28%
• Dividend yield: 0.02%

AstraZeneca PLC investor discussion

8 recent posts · 6 bullish · 0 bearish · 2 neutral.

• [Bullish] AZN 신약 파이프라인 기대되네 ㅋㅋ PER 13배면 저평가 영역인 듯 ㅋㅋ 존버 갑니다~
• [Bullish] AZN 신약 파이프라인 기대되네. PER 13배면 저평가 영역인 듯 ㅋㅋ
• [Bullish] AZN 신약 파이프라인 기대되네. PER 13배로 저평가 영역인 듯.
• [Neutral] AZN 신약 파이프라인 기대되는데 승인 리스크도 있음. 리스크 분산 전략 필요할 듯
• [Bullish] AZN 신약 파이프라인 긍정적이네. PER 13배로 저평가 영역이라 리스크 분산해도 괜찮을 듯.

Frequently asked questions